Zurich Cantonal Bank
MLTX icon

Zurich Cantonal Bank’s MoonLake Immunotherapeutics MLTX Stock Holding History

Zurich Cantonal Bank’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$374K Hold
19,229
– – ﹤0.01% 2088
2026
Q1 		$358K Buy
19,229
+5,637
+41% +$93.4K ﹤0.01% 2005
2025
Q4 		$179K Buy
13,592
+7,673
+130% +$90.5K ﹤0.01% 2257
2025
Q3 		$42.4K Buy
5,919
+3,166
+115% +$165K ﹤0.01% 2461
2025
Q2 		$130K Hold
2,753
– – ﹤0.01% 2310
2025
Q1 		$108K Hold
2,753
– – ﹤0.01% 2364
2024
Q4 		$149K Hold
2,753
– – ﹤0.01% 2278
2024
Q3 		$139K Hold
2,753
– – ﹤0.01% 2291
2024
Q2 		$121K Sell
2,753
-1,277
-32% -$54.1K ﹤0.01% 2299
2024
Q1 		$202K Buy
4,030
+441
+12% +$23.9K ﹤0.01% 2044
2023
Q4 		$217K Buy
+3,589
New +$185K ﹤0.01% 2035

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Zurich Cantonal Bank's MLTX Position: Q2 2026 in Review

Zurich Cantonal Bank held its MoonLake Immunotherapeutics (MLTX) position steady in Q2 2026 at 19,229 shares worth $374K. The position accounts for ﹤0.01% of the portfolio, ranked #2088.

Zurich Cantonal Bank first reported a position in MLTX in Q4 2023 and has held it in 11 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Zurich Cantonal Bank held 19,229 shares of MoonLake Immunotherapeutics worth $374K as of Q2 2026.
  • Zurich Cantonal Bank left its MoonLake Immunotherapeutics share count unchanged in Q2 2026.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2088 holding.
  • Zurich Cantonal Bank first reported a position in MoonLake Immunotherapeutics in Q4 2023 and has held it in 11 quarters since.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.